Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience.

Abstract

The direct and indirect effects of Coronavirus Disease-19 (COVID-19) pandemic, on Italian patients with lysosomal storage disorders receiving therapy, were analyzed by a phone questionnaire. No proved COVID-19 emerged among 102 interviewed. No problems were reported by patients receiving oral treatments. Forty-nine% of patients receiving enzyme replacement therapy in hospitals experienced disruptions, versus 6% of those home-treated. The main reasons of missed infusions were fear of infection (62.9%) and re-organization of the infusion centers (37%).

• Authors: Annalisa Sechi, Daniela Macor, Serena Valent, Rosalia Maria Da Riol, Manuela Zanatta, Alessandro Spinelli, Katja Bianchi, Nadia Bertossi, Andrea Dardis, Francesca Valent, Maurizio Scarpa
• Journal: Molecular genetics and metabolism (Mol Genet Metab) Vol. 130 Issue 3 Pg. 170-171 (07 2020) ISSN: 1096-7206 [Electronic] United States
• PMID: 32386848 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Topics

• Adult
• COVID-19
• Coronavirus Infections (complications, epidemiology, psychology, therapy)
• Enzyme Replacement Therapy
• Fear
• Female
• Humans
• Italy (epidemiology)
• Lysosomal Storage Diseases (complications, therapy)
• Male
• Middle Aged
• Pandemics
• Patient Acceptance of Health Care
• Patient Care Management
• Pneumonia, Viral (complications, epidemiology, psychology, therapy)
• Surveys and Questionnaires
• Young Adult